Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Reduced Intensity Conditioning Regimens

Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia

Summary:

Reduced-intensity conditioning that harnesses the potential of a graft-versus-tumor (GVT) effect has been proposed as an alternative to conventional myeloablative allogeneic stem cell transplantation. The primary aim is engraftment and this can be achieved with minimal immunosuppression. In this report, we describe the use of such regimens for CML in 17 patients who received human leukocyte antigen (HLA)-matched sibling allografts. Conditioning was with fludarabine, antithymocyte globulin (ATG) and busulfan for the first 11 patients, whereas fludarabine, busulfan and TBI were used for the remaining six patients. Engraftment was prompt in most of the cases. Complications and need for supportive therapy in the immediate post-transplant period were reduced drastically. Only two patients (both in the TBI group) died within the first 100 days. Acute graft-versus-host disease (GVHD) grade II–IV was seen in seven patients. Complications occurred later on. Chronic GVHD was observed in 11/17 patients. Lung infection and GVHD were the major killers. In surviving patients, after a median follow-up of 30 months (range 37–21 months), 6/17 (35.3%) are alive. Five are disease free and one patient is still in relapse even after a second donor lymphocyte infusion. Total treatment time and cost were more than with conventional transplants. We conclude that reduced-intensity transplantation still requires further refinement.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure1

Similar content being viewed by others

References

  1. Passweg JR, Rowlings PA, Armitage JO et al. Report from the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry—North America. In: Cecka JM, Terasaki PI (eds) Clinical Transplants. UCLA Tissue Typing Laboratory: Los Angeles, CA, 1996, 117 pp.

    Google Scholar 

  2. Weiden PL, Sullivan KM, Flournoy N et al. The Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Eng J Med 1981; 304: 1529–1533.

    Article  CAS  Google Scholar 

  3. Kolb HJ, Mittermuller J, Clemn CH et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465.

    CAS  PubMed  Google Scholar 

  4. Slavin S, Nagler A, Naperstek E et al. Non myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic disease. Blood 1998; 91: 756–763.

    CAS  PubMed  Google Scholar 

  5. McSweeney P, Storb R . Establishing mixed chimerism with immunosuppressive, minimally myelosuppressive conditioning. American Society of Hematology Educational Book. 1999, pp 396–405.

  6. McSweeney PA, Neiderwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–3400.

    Article  CAS  PubMed  Google Scholar 

  7. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy. Blood 1997; 89: 4531–4536.

    CAS  PubMed  Google Scholar 

  8. Saikia TK, Advani SH, Parikh PM et al. Results of allogeneic bone marrow transplant in chronic myeloid leukemia following conditioning with busulfan and cyclophosphamide. J Assoc Physicians India 1999; 47: 770–773.

    CAS  PubMed  Google Scholar 

  9. Roosnek E, Hogendijk S, Zawadynski S et al. The frequency of pretransplant donor cytotoxic T cells precursors with anti-host specificity predicts survival of patients transplanted with bone marrow from donors other than HLA identical siblings. Transplantation 1993; 56: 691–696.

    Article  CAS  PubMed  Google Scholar 

  10. Cheson B . Infection and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431–2448.

    Article  CAS  PubMed  Google Scholar 

  11. Panigrahi S, Varadi G, Or R et al. Invasive fungal infections in patients undergoing fully matched allogeneic stem cell transplantation (allo SCT) following non-myeloablative conditioning. Blood 1999; 94 (Suppl. 1): 339a.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Das, M., Saikia, T., Advani, S. et al. Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplant 32, 125–129 (2003). https://doi.org/10.1038/sj.bmt.1704107

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704107

Keywords

This article is cited by

Search

Quick links